Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

38
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
38
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

342
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
342
Dementia01:30

Dementia

74
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
74
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

B1a Cell-IgM Axis Protects Against Hypertension by Blunting IFNγ+CD4+T Cells.

Circulation research·2026
Same author

Mean warming enhances insect resilience to high temperatures: species-specific evidence from two wheat aphids.

Journal of insect physiology·2026
Same author

Dynamic pendulum strategy enables both anti-quenching and fast spin flipping for efficient blue multiple-resonance thermally activated delayed fluorescence emitters.

Chemical science·2026
Same author

Modulation of Donor-Acceptor Stacking in Viologen Coordination Polymers toward Enhanced Multimodal Photoresponsive Properties.

Inorganic chemistry·2026
Same author

Cargo molecules in plasma neural-derived extracellular vesicles reveal pathological signatures of primary open-angle glaucoma.

Journal of translational medicine·2026
Same author

TCHP drives hepatocarcinogenesis through LLPS-mediated AURKA condensation and enables synergistic therapy.

Cell death & disease·2026

Related Experiment Video

Updated: May 15, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.7K

C-reactive protein-mediated dementia.

Jia-Ming Tang1, Qing Lu1, Han-Xiao Lin2

  • 1Department of Neurology, the Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi, China.

Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society
|April 7, 2025
PubMed
Summary
This summary is machine-generated.

C-reactive protein (CRP) is linked to dementia risk and progression. Elevated CRP levels in healthy individuals may predict future Alzheimer's disease (AD), suggesting its potential for early screening.

Keywords:
Alzheimer's diseaseC‐reactive proteininflammatorymild cognitive impairment

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.7K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.1K

Related Experiment Videos

Last Updated: May 15, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.7K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.7K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.1K

Area of Science:

  • Neuroscience
  • Immunology
  • Gerontology

Background:

  • Dementia, particularly Alzheimer's disease (AD), is a leading cause of disability and mortality, characterized by memory loss and personality changes.
  • Neurological damage in AD is irreversible, and current treatments for dementia are limited.
  • Inflammatory responses are implicated in cognitive impairment, with elevated C-reactive protein (CRP) levels associated with increased AD risk.

Purpose of the Study:

  • To review the relationship between C-reactive protein (CRP) and different types of dementia.
  • To explore the role of CRP in the development of cognitive impairment.
  • To assess the potential of CRP testing for early AD screening and progression monitoring.

Main Methods:

  • Literature review focusing on studies examining C-reactive protein (CRP) and dementia.
  • Analysis of research linking inflammatory markers to cognitive decline.
  • Evaluation of CRP as a predictor for neurodegenerative diseases.

Main Results:

  • Elevated C-reactive protein (CRP) levels in healthy individuals are associated with an increased likelihood of developing Alzheimer's disease (AD).
  • CRP is a recognized risk factor and predictor for neurodegenerative diseases.
  • CRP testing is accessible and cost-effective, indicating its potential clinical utility.

Conclusions:

  • C-reactive protein (CRP) plays a significant role in the pathogenesis of dementia, including Alzheimer's disease (AD).
  • CRP testing offers a promising, cost-effective tool for the early detection and monitoring of dementia progression.
  • Further research into CRP's mechanisms in cognitive impairment could lead to novel therapeutic strategies.